JP2006131575A - 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 - Google Patents
低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 Download PDFInfo
- Publication number
- JP2006131575A JP2006131575A JP2004324234A JP2004324234A JP2006131575A JP 2006131575 A JP2006131575 A JP 2006131575A JP 2004324234 A JP2004324234 A JP 2004324234A JP 2004324234 A JP2004324234 A JP 2004324234A JP 2006131575 A JP2006131575 A JP 2006131575A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- low
- drug
- parts
- melting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 67
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 229940079593 drug Drugs 0.000 title claims abstract description 55
- 238000002844 melting Methods 0.000 title claims abstract description 40
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000378 calcium silicate Substances 0.000 claims abstract description 35
- 229910052918 calcium silicate Inorganic materials 0.000 claims abstract description 35
- 229920002472 Starch Polymers 0.000 claims abstract description 19
- 235000019698 starch Nutrition 0.000 claims abstract description 18
- 239000011230 binding agent Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 229920001353 Dextrin Polymers 0.000 claims abstract description 8
- 239000004375 Dextrin Substances 0.000 claims abstract description 8
- 235000019425 dextrin Nutrition 0.000 claims abstract description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 7
- 230000008018 melting Effects 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 238000000748 compression moulding Methods 0.000 claims description 3
- JHXCINJSAAFBDH-UHFFFAOYSA-N [Ca].O[Si](O)(O)O Chemical compound [Ca].O[Si](O)(O)O JHXCINJSAAFBDH-UHFFFAOYSA-N 0.000 claims 1
- 238000005469 granulation Methods 0.000 description 14
- 230000003179 granulation Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000004570 mortar (masonry) Substances 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- -1 epilysole Chemical compound 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-ASMJPISFSA-N alpha-maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-ASMJPISFSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004992 maprotiline hydrochloride Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- ZHVULPDNOFUIML-UHFFFAOYSA-N octane;hydrochloride Chemical compound Cl.CCCCCCCC ZHVULPDNOFUIML-UHFFFAOYSA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】イブプロフェン等の低融点薬剤100重量部、多孔性の珪酸カルシウム35〜100重量部、デキストリン等のデンプン類25〜80重量部、および結合剤1〜15重量部を含んでなる組成物により構成されてなり、ゆるみ嵩密度が0.25〜0.80g/mlである低融点薬剤含有顆粒。
【選択図】 なし
Description
薬剤の有効となる量が大きいこと、すなわち1錠中への投入量が多いことや、スティッキングを起こし易いことなどより最適である。
2CaO・3SiO2・mSiO2・nH2O
(式中、1<m<2、2<n<3である。)
を有し、電子顕微鏡で観察して花弁状結晶構造を有するジャイロライト型珪酸カルシウム粉末が挙げられ、具体的には商品名「フローライト」(株式会社トクヤマ製)として市販されている。
以下、実施例を示して本発明をさらに詳細に説明するが、本発明はこれらの実施例に何ら制限されるものではない。
・ゆるみ嵩密度の測定
ゆるみ嵩密度は、定量カップを用いる方法により求められた。この方法は、疎充填状態でのみかけ嵩密度を測定するもので、一定容量の円柱状カップに、やや多めの試料粉体を注ぎ込み、へらですりきって重量を測定するものである。疎充填状態を作る方法として、支持台に設置した漏斗から流し込む方法が採用された。
実施例1
商品名「バーチカルグラニュレーター」(株式会社パウレック製)に、平均粒径が20〜30μmであり、見掛比重が8〜12g/lであるジャイロライト型の多孔性珪酸カルシウム粉末(商品名「フローライトRE」 株式会社トクヤマ製)66重量部を投入した。次いで、イブプロフェン100重量部をエタノール70重量部に溶解させ、これを添加して23〜25℃下でブレード200rpm、クロススクリュー3000rpmの回転条件で5分間攪拌して、上記珪酸カルシウム粉末に吸着、担持させて薬剤担持珪酸カルシウム粉末とした。
実施例1において、イブプロフェン100重量部に対して配合する多孔性の珪酸カルシウム、マルトデキストリン、ヒドロキシプロピルセルロースの配合量を表1のようにそれぞれ変更した以外は、実施例1と同様にして顆粒を製造し、さらにその顆粒を用いて錠剤を製造した。
実施例1において、デキストリンに代えて結晶セルロースを45重量部を用いる以外は、実施例1と同様に実施して顆粒を製造した。得られた顆粒は、平均粒径が75μmであり、ゆるみ嵩密度が0.25g/mlであった。
Claims (7)
- 低融点薬剤100重量部、多孔性の珪酸カルシウム35〜100重量部、デンプン類25〜80重量部、および結合剤1〜15重量部を含んでなる組成物により構成されてなり、ゆるみ嵩密度が0.25〜0.80g/mlである低融点薬剤含有顆粒。
- 低融点薬剤がイブプロフェンである請求項1記載の低融点薬剤含有顆粒。
- 低融点薬剤の少なくとも一部が、多孔性の珪酸カルシウムに吸着、担持されてなる請求項1または請求項2記載の低融点薬剤含有顆粒。
- デンプン類がデキストリンである請求項1〜3のいずれか一項に記載の低融点薬剤含有顆粒。
- 請求項1〜4のいずれか一項に記載の低融点薬剤含有顆粒を圧縮成形してなる錠剤。
- 低融点薬剤100重量部を有機溶液に溶解させた溶液と、多孔性の珪酸カルシウム35〜100重量部とを混合して低融点薬剤を該珪酸カルシウムに吸着、担持させた後、当該薬剤担持珪酸カルシウムと、デンプン類25〜80重量部、結合剤1〜15重量部とを混合し、次いで、得られた原料粉末組成物を造粒して、ゆるみ嵩密度が0.25〜0.80g/mlである低融点薬剤含有顆粒を製造することを特徴とする請求項1記載の低融点薬剤含有顆粒の製造方法。
- 請求項1記載の製造方法に従って低融点薬剤含有顆粒を製造した後、得られた低融点薬剤含有顆粒を圧縮成形することを特徴とする請求項4記載の錠剤の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004324234A JP4717414B2 (ja) | 2004-11-08 | 2004-11-08 | 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004324234A JP4717414B2 (ja) | 2004-11-08 | 2004-11-08 | 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006131575A true JP2006131575A (ja) | 2006-05-25 |
JP4717414B2 JP4717414B2 (ja) | 2011-07-06 |
Family
ID=36725432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004324234A Active JP4717414B2 (ja) | 2004-11-08 | 2004-11-08 | 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4717414B2 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097333A1 (ja) * | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | 顆粒、錠剤およびそれらの製造方法 |
WO2009044854A1 (ja) * | 2007-10-03 | 2009-04-09 | Asahi Breweries, Ltd. | 顆粒、錠剤およびそれらの製造方法 |
JP2010030903A (ja) * | 2007-06-25 | 2010-02-12 | Kowa Co | イブプロフェン、トラネキサム酸及びケイ酸カルシウムを含有する固形製剤 |
JP2011213714A (ja) * | 2010-03-15 | 2011-10-27 | Taisho Pharmaceutical Co Ltd | イブプロフェン含有固形製剤の製造方法 |
JP2012144520A (ja) * | 2010-12-24 | 2012-08-02 | Lion Corp | 錠剤 |
JP2013010713A (ja) * | 2011-06-29 | 2013-01-17 | Tokyo Metropolitan Industrial Technology Research Institute | 無機有機複合粒子及びその製造方法 |
JP2014080305A (ja) * | 2012-10-14 | 2014-05-08 | Tomita Pharmaceutical Co Ltd | ケイ酸カルシウム系材料及びその製造方法 |
JP2015232030A (ja) * | 2009-04-01 | 2015-12-24 | ノヴィファーマ ソシエテ アノニム | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 |
JP2016222648A (ja) * | 2015-05-26 | 2016-12-28 | 大正製薬株式会社 | 固形製剤 |
RU2673239C2 (ru) * | 2013-03-13 | 2018-11-23 | Трис Фарма, Инк. | Твердые таблетки и капсулы модифицированного высвобождения бензонатата |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0352823A (ja) * | 1989-07-21 | 1991-03-07 | Tokuyama Soda Co Ltd | 固形剤 |
JPH10114655A (ja) * | 1996-10-09 | 1998-05-06 | Kyowa Hakko Kogyo Co Ltd | 固形製剤 |
WO2000027393A1 (fr) * | 1998-11-06 | 2000-05-18 | Fuji Chemical Industry Co., Ltd. | Poudres contenant des trocotrienols, procede de production de ces poudres et comprimes prepares par moulage par compression de ces poudres |
WO2003030868A1 (en) * | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
-
2004
- 2004-11-08 JP JP2004324234A patent/JP4717414B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0352823A (ja) * | 1989-07-21 | 1991-03-07 | Tokuyama Soda Co Ltd | 固形剤 |
JPH10114655A (ja) * | 1996-10-09 | 1998-05-06 | Kyowa Hakko Kogyo Co Ltd | 固形製剤 |
WO2000027393A1 (fr) * | 1998-11-06 | 2000-05-18 | Fuji Chemical Industry Co., Ltd. | Poudres contenant des trocotrienols, procede de production de ces poudres et comprimes prepares par moulage par compression de ces poudres |
WO2003030868A1 (en) * | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097333A1 (ja) * | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | 顆粒、錠剤およびそれらの製造方法 |
JPWO2007097333A1 (ja) * | 2006-02-20 | 2009-07-16 | アサヒビール株式会社 | 顆粒、錠剤およびそれらの製造方法 |
JP2010030903A (ja) * | 2007-06-25 | 2010-02-12 | Kowa Co | イブプロフェン、トラネキサム酸及びケイ酸カルシウムを含有する固形製剤 |
WO2009044854A1 (ja) * | 2007-10-03 | 2009-04-09 | Asahi Breweries, Ltd. | 顆粒、錠剤およびそれらの製造方法 |
JP2015232030A (ja) * | 2009-04-01 | 2015-12-24 | ノヴィファーマ ソシエテ アノニム | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 |
JP2011213714A (ja) * | 2010-03-15 | 2011-10-27 | Taisho Pharmaceutical Co Ltd | イブプロフェン含有固形製剤の製造方法 |
JP2012144520A (ja) * | 2010-12-24 | 2012-08-02 | Lion Corp | 錠剤 |
JP2013010713A (ja) * | 2011-06-29 | 2013-01-17 | Tokyo Metropolitan Industrial Technology Research Institute | 無機有機複合粒子及びその製造方法 |
JP2014080305A (ja) * | 2012-10-14 | 2014-05-08 | Tomita Pharmaceutical Co Ltd | ケイ酸カルシウム系材料及びその製造方法 |
RU2673239C2 (ru) * | 2013-03-13 | 2018-11-23 | Трис Фарма, Инк. | Твердые таблетки и капсулы модифицированного высвобождения бензонатата |
JP2016222648A (ja) * | 2015-05-26 | 2016-12-28 | 大正製薬株式会社 | 固形製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP4717414B2 (ja) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
WO2007097333A1 (ja) | 顆粒、錠剤およびそれらの製造方法 | |
NO314124B1 (no) | Fremgangsmåte for fremstilling av partikler | |
WO2008101943A1 (en) | Pharmaceutical metformin hydrochloride formulation and tablet comprising said formulation | |
JP4717414B2 (ja) | 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 | |
JP5184383B2 (ja) | ドンペリドン口腔内崩壊錠剤 | |
BRPI0809282B1 (pt) | material granular, material de partida para uma forma de dosagem, forma de dosagem, processo de compressão direta para preparar uma forma de dosagem, uso do material granular e processo para granular um pó de polímero | |
JP6759390B2 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
RU2207133C2 (ru) | Стабилизированные композиции тиболона | |
MX2015000971A (es) | Formulaciones y metodos para elaborar formulaciones para utilizarse en evacuacion colonica. | |
JP2016117738A (ja) | シロドシン−シクロデキストリン包接化合物 | |
JP4925526B2 (ja) | 薬物の混合方法 | |
JP2006143650A (ja) | 付着性の高い薬物を含有する錠剤の製造方法 | |
JP2017071558A (ja) | 錠剤の衝撃耐性改善賦形剤 | |
WO2022004871A1 (ja) | 錠剤およびその製造方法 | |
JP4774739B2 (ja) | 漢方エキス含有錠剤組成物およびその製造方法 | |
JP2669517B2 (ja) | ロキソプロフェン・ナトリウム含有固形製剤 | |
CA2747345C (en) | Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability | |
JPH05105636A (ja) | 制酸剤組成物 | |
JP3059149B2 (ja) | テトラヒドロリプスタチン含有組成物 | |
EP0319074A1 (en) | Pharmaceutical composition and process for its preparation | |
EP2671569A1 (en) | Stable pharmaceutical compositions with fast onset | |
JP2019089758A (ja) | セレコキシブ含有錠剤における溶出性の改善方法 | |
JP2002173428A (ja) | クラリスロマイシン錠剤およびその製造法 | |
EA005596B1 (ru) | Твёрдая лекарственная форма, включающая циталопрам |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070516 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20101001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101001 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110128 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110315 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110330 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4717414 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140408 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |